keyword
MENU ▼
Read by QxMD icon Read
search

R Guyton

keyword
https://www.readbyqxmd.com/read/29606395/from-the-editor-weighing-the-advantages-of-lipid-conference-and-journal
#1
EDITORIAL
John R Guyton
No abstract text is available yet for this article.
March 2018: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29583081/lipid-effects-of-icosapent-ethyl-in-women-with-diabetes-mellitus-and-persistent-high-triglycerides-on-statin-treatment-anchor-trial-subanalysis
#2
Eliot A Brinton, Christie M Ballantyne, John R Guyton, Sephy Philip, Ralph T Doyle, Rebecca A Juliano, Lori Mosca
BACKGROUND: High triglycerides (TG) and diabetes mellitus type 2 (DM2) are stronger predictors of cardiovascular disease (CVD) in women than in men, but few randomized, controlled clinical trials have investigated lipid-lowering interventions in women and none have reported results specifically in women with high TG and DM2. Icosapent ethyl (Vascepa) is pure prescription eicosapentaenoic acid (EPA) ethyl ester approved at 4 g/day as an adjunct to diet to reduce TG ≥500 mg/dL. METHODS: The 12-week ANCHOR trial randomized 702 statin-treated patients (73% with DM; 39% women) at increased CVD risk with TG 200-499 mg/dL despite controlled low-density lipoprotein cholesterol (LDL-C; 40-99 mg/dL) to receive icosapent ethyl 2 g/day, 4 g/day, or placebo...
March 27, 2018: Journal of Women's Health
https://www.readbyqxmd.com/read/29452916/from-the-editor-a-run-of-success-in-treating-atherosclerotic-vascular-disease
#3
EDITORIAL
John R Guyton
No abstract text is available yet for this article.
January 2018: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29409728/relations-of-glyca-and-lipoprotein-particle-subspecies-with-cardiovascular-events-and-mortality-a-post-hoc-analysis-of-the-aim-high-trial
#4
James D Otvos, John R Guyton, Margery A Connelly, Sydney Akapame, Vera Bittner, Steven L Kopecky, Megan Lacy, Santica M Marcovina, Joseph B Muhlestein, William E Boden
BACKGROUND: The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial showed no incremental benefit of extended-release niacin (ERN) therapy added to simvastatin in subjects with cardiovascular disease (CVD). OBJECTIVES: To examine the effects of ERN treatment on lipoprotein particles and GlycA, a new marker of systemic inflammation, and their relations with incident CVD events including mortality...
March 2018: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29157664/from-the-editor
#5
EDITORIAL
John R Guyton
No abstract text is available yet for this article.
November 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29080546/health-disparities-among-adult-patients-with-a-phenotypic-diagnosis-of-familial-hypercholesterolemia-in-the-cascade-fh%C3%A2-patient-registry
#6
Stephen M Amrock, P Barton Duell, Thomas Knickelbine, Seth S Martin, Emily C O'Brien, Karol E Watson, Joanna Mitri, Iris Kindt, Peter Shrader, Seth J Baum, Linda C Hemphill, Catherine D Ahmed, Rolf L Andersen, Iftikhar J Kullo, Dervilla McCann, John A Larry, Michael F Murray, Robert Fishberg, John R Guyton, Katherine Wilemon, Matthew T Roe, Daniel J Rader, Christie M Ballantyne, James A Underberg, Paul Thompson, Dannielle Duffy, MacRae F Linton, Michael D Shapiro, Patrick M Moriarty, Joshua W Knowles, Zahid S Ahmad
BACKGROUND AND AIMS: Most familial hypercholesterolemia (FH) patients remain undertreated, and it is unclear what role health disparities may play for FH patients in the US. We sought to describe sex and racial/ethnic disparities in a national registry of US FH patients. METHODS: We analyzed data from 3167 adults enrolled in the CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia (CASCADE-FH) registry. Logistic regression was used to evaluate for disparities in LDL-C goals and statin use, with adjustments for covariates including age, cardiovascular risk factors, and statin intolerance...
December 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28943037/from-the-editor
#7
EDITORIAL
John R Guyton
No abstract text is available yet for this article.
September 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28927896/niacin-and-heart-disease-prevention-engraving-its-tombstone-is-a-mistake
#8
REVIEW
Harold Robert Superko, Xue-Qiao Zhao, Howard N Hodis, John R Guyton
Niacin (nicotinic acid) has been used for primary and secondary coronary heart disease prevention for over 40 years. Until recently clinical trials incorporating niacin as part of an intervention strategy consistently demonstrated reduction in clinical events and lesion improvement, including ≥6% absolute mortality reduction. Two large clinical event trials in 2011 (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) and 2014 (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) concluded that niacin added to statin therapy did not provide clinical event benefit over statin alone...
November 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28869141/marine-omega-3-fatty-acids-and-cardiac-death
#9
EDITORIAL
John R Guyton
No abstract text is available yet for this article.
September 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28637271/logical-issues-with-the-pressure-natriuresis-theory-of-chronic-hypertension
#10
Theodore W Kurtz, Stephen E DiCarlo, R Curtis Morris
The term "abnormal pressure natriuresis" refers to a subnormal effect of a given level of blood pressure (BP) on sodium excretion. It is widely believed that abnormal pressure natriuresis causes an initial increase in BP to be sustained. We refer to this view as the "pressure natriuresis theory of chronic hypertension." The proponents of the theory contend that all forms of chronic hypertension are sustained by abnormal pressure natriuresis, irrespective of how hypertension is initiated...
December 1, 2016: American Journal of Hypertension
https://www.readbyqxmd.com/read/28457169/arthroscopic-correlates-of-subtle-syndesmotic-injury
#11
Gregory P Guyton, Kenneth DeFontes, Cameron R Barr, Brent G Parks, Lyn M Camire
BACKGROUND: Arthroscopic criteria for identifying syndesmotic disruption have been variable and subjective. We aimed to quantify syndesmotic disruption arthroscopically using a standardized measurement device. METHODS: Ten cadaveric lower extremity specimens were tested in intact state and after serial sectioning of the syndesmotic structures (anterior inferior tibiofibular ligament [AiTFL], interosseous ligament [IOL], posterior inferior tibiofibular ligament [PiTFL], deltoid)...
May 2017: Foot & Ankle International
https://www.readbyqxmd.com/read/28407048/response-to-tautological-nature-of-guyton-s-theory-of-blood-pressure-control
#12
Theodore W Kurtz, Stephen E DiCarlo, R Curtis Morris
No abstract text is available yet for this article.
July 1, 2017: American Journal of Hypertension
https://www.readbyqxmd.com/read/27999936/lack-of-evidence-for-tissue-hypoxia-as-a-contributing-factor-in-anastomotic-leak-following-colon-anastomosis-and-segmental-devascularization-in-rats
#13
B A Shakhsheer, B Lec, A Zaborin, K Guyton, A M Defnet, N Bagrodia, J J Kandel, O Zaborina, S L Hernandez, J Alverdy
PURPOSE: Current surgical dogma dictates that tissue ischemia and hypoxia are major contributing factors in anastomotic leak despite scant evidence. The aim of this study was to determine if tissue hypoxia is a feature of anastomotic leakage in rats following colon resection and segmental devascularization. METHODS: Rats were randomly assigned to undergo sham operation, segmental colon devascularization alone, colectomy alone, or segmental devascularization plus colectomy...
April 2017: International Journal of Colorectal Disease
https://www.readbyqxmd.com/read/27939227/usefulness-of-icosapent-ethyl-eicosapentaenoic-acid-ethyl-ester-in-women-to-lower-triglyceride-levels-results-from-the-marine-and-anchor-trials
#14
RANDOMIZED CONTROLLED TRIAL
Lori Mosca, Christie M Ballantyne, Harold E Bays, John R Guyton, Sephy Philip, Ralph T Doyle, Rebecca A Juliano
There are limited data on the efficacy and safety of triglyceride (TG)-lowering agents in women. We conducted subgroup analyses of the effects of icosapent ethyl (a high-purity prescription form of the ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid) on TG levels (primary efficacy variable) and other atherogenic and inflammatory parameters in a total of 215 women with a broad range of TG levels (200-2000 mg/dl) enrolled in two 12-week placebo-controlled trials: MARINE (n = 18; placebo, n = 18) and ANCHOR (n = 91; placebo, n = 88)...
February 1, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/27625344/efficacy-and-safety-of-alirocumab-150-mg-every-4-weeks-in-patients-with-hypercholesterolemia-not-on-statin-therapy-the-odyssey-choice-ii-study
#15
RANDOMIZED CONTROLLED TRIAL
Erik Stroes, John R Guyton, Norman Lepor, Fernando Civeira, Daniel Gaudet, Gerald F Watts, Marie T Baccara-Dinet, Guillaume Lecorps, Garen Manvelian, Michel Farnier
BACKGROUND: The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone. METHODS AND RESULTS: Patients were randomly assigned to placebo, alirocumab 150 mg Q4W or 75 mg Q2W (calibrator arm), with dose adjustment to 150 mg Q2W at week (W) 12 if W8 predefined LDL-C target levels were not met...
September 13, 2016: Journal of the American Heart Association
https://www.readbyqxmd.com/read/27618825/efficacy-and-safety-of-alirocumab-in-patients-with-heterozygous-familial-hypercholesterolemia-and-ldl-c-of-160-mg-dl-or-higher
#16
RANDOMIZED CONTROLLED TRIAL
Henry N Ginsberg, Daniel J Rader, Frederick J Raal, John R Guyton, Marie T Baccara-Dinet, Christelle Lorenzato, Robert Pordy, Erik Stroes
PURPOSE: Even with statins and other lipid-lowering therapy (LLT), many patients with heterozygous familial hypercholesterolemia (heFH) continue to have elevated low-density lipoprotein cholesterol (LDL-C) levels. ODYSSEY HIGH FH (NCT01617655) assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 monoclonal antibody, versus placebo in patients with heFH and LDL-C ≥ 160 mg/dl despite maximally tolerated statin ± other LLT. METHODS: Patients were randomized to subcutaneous alirocumab 150 mg or placebo every 2 weeks (Q2W) for 78 weeks...
October 2016: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/27578122/triglyceride-lowering-therapies-reduce-cardiovascular-disease-event-risk-in-subjects-with-hypertriglyceridemia
#17
Kevin C Maki, John R Guyton, Carl E Orringer, Ian Hamilton-Craig, Dominik D Alexander, Michael H Davidson
BACKGROUND: Cardiovascular outcomes trials of fibrates, niacin, or omega-3 fatty acids alone, or added to a statin, have not consistently demonstrated reduced risk, but larger, statistically significant clinical benefits have been reported in subgroups with elevated triglycerides (TG) and/or elevated TG plus low high-density lipoprotein cholesterol (HDL-C). OBJECTIVE: To perform a meta-analysis of the effects of therapies targeting TG and TG-rich lipoprotein cholesterol on cardiovascular disease event risk in subjects with elevated TG or elevated TG paired with low HDL-C...
July 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27578118/statin-intolerance-in-a-referral-lipid-clinic
#18
Wanda C Lakey, Nicole G Greyshock, Carly E Kelley, Mohammad A Siddiqui, Umar Ahmad, Yuliya V Lokhnygina, John R Guyton
BACKGROUND: Statins effectively prevent atherosclerotic cardiovascular disease, but rates of statin discontinuation after adverse events are high. OBJECTIVE: Describe the range and relative frequencies of adverse events potentially attributable to statins in lipid referral practice and assess statin rechallenge outcomes. METHODS: Retrospective cohort study of 642 patients with statin-associated adverse events evaluated in a referral lipid clinic between January 1, 2004 and January 27, 2011...
July 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27530446/morphine-promotes-colonization-of-anastomotic-tissues-with-collagenase-producing-enterococcus-faecalis-and-causes-leak
#19
Baddr A Shakhsheer, Luke A Versten, James N Luo, Jennifer R Defazio, Robin Klabbers, Scott Christley, Alexander Zaborin, Kristina L Guyton, Monika Krezalek, Daniel P Smith, Nadim J Ajami, Joseph F Petrosino, Irma D Fleming, Natalia Belogortseva, Olga Zaborina, John C Alverdy
BACKGROUND: Despite ever more powerful antibiotics, newer surgical techniques, and enhanced recovery programs, anastomotic leaks remain a clear and present danger to patients. Previous work from our laboratory suggests that anastomotic leakage may be caused by Enterococcus faecalis strains that express a high collagenase phenotype (i.e., collagenolytic). Yet the mechanisms by which the practice of surgery shifts or selects for collagenolytic phenotypes to colonize anastomotic tissues remain unknown...
October 2016: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/27412149/a-proposed-framework-for-the-systematic-review-and-integrated-assessment-syrina-of-endocrine-disrupting-chemicals
#20
REVIEW
Laura N Vandenberg, Marlene Ågerstrand, Anna Beronius, Claire Beausoleil, Åke Bergman, Lisa A Bero, Carl-Gustaf Bornehag, C Scott Boyer, Glinda S Cooper, Ian Cotgreave, David Gee, Philippe Grandjean, Kathryn Z Guyton, Ulla Hass, Jerrold J Heindel, Susan Jobling, Karen A Kidd, Andreas Kortenkamp, Malcolm R Macleod, Olwenn V Martin, Ulf Norinder, Martin Scheringer, Kristina A Thayer, Jorma Toppari, Paul Whaley, Tracey J Woodruff, Christina Rudén
BACKGROUND: The issue of endocrine disrupting chemicals (EDCs) is receiving wide attention from both the scientific and regulatory communities. Recent analyses of the EDC literature have been criticized for failing to use transparent and objective approaches to draw conclusions about the strength of evidence linking EDC exposures to adverse health or environmental outcomes. Systematic review methodologies are ideal for addressing this issue as they provide transparent and consistent approaches to study selection and evaluation...
July 14, 2016: Environmental Health: a Global Access Science Source
keyword
keyword
58769
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"